Table 2.

(A): Clinical staging of study participants for years 2019 and 2020. (B): Pathologic staging of study participants for years 2019 and 2020. Upstaging calculated as described in the methods section. T = Tumor, N=Nodal, M = Metastases. Bolded p-value indicates statistical significance (p < 0.05).

A. Clinical staging	Year 2019	Year 2020	p-Value
	(n = 134)	(n = 134)
	n (%)	n (%)
Clinical T stage
0	13 (9.7%)	6 (4.5%)	0.488
1	22 (16.4%)	25 (18.7%)
2	39 (29.1%)	34 (25.4%)
3	25 (18.7%)	34 (25.4%)
4	14 (10.4%)	18 (13.4%)
4a	18 (13.4%)	15 (11.2%)
4b	3 (2.2%)	2 (1.5%)
Clinical N stage
0	69 (51.5%)	57 (42.5%)	0.028
1	33 (24.6%)	32 (23.9%)
2	7 (5.2%)	9 (6.7%)
2a	5 (3.7%)	0 (0%)
2b	10 (7.5%)	19 (14.2%)
2c	4 (3.0%)	12 (9.0%)
3	3 (2.2%)	1 (0.7%)
3a	0 (0%)	2 (1.5%)
3b	3 (2.2%)	2 (1.5)
Clinical M stage
0	131 (97.8%)	128 (95.5%)	0.5
1	3 (2.2%)	6 (4.5%)

B. Pathologic staging & upstaging	Year 2019	Year 2020	p-Value
	(n = 77)	(n = 69)
	n (%)	N (%)
Pathologic T stage
0	10 (13.0%)	4 (5.8%)	0.368
1	8 (10.4%)	15 (21.7%)
2	18 (23.4%)	13 (18.8%)
3	16 (20.8%)	14 (20.3%)
4	1 (1.3%)	2 (2.9%)
4a	21 (27.3%)	20 (29.0%)
4b	3 (3.9%)	1 (1.4%)
Pathologic N stage
0	40 (51.9%)	39 (56.5%)	0.993
1	13 (16.9%)	11 (15.9%)
2	2 (2.6%)	1 (1.4%)
2a	3 (3.9%)	2 (2.9%)
2b	7 (9.1%)	5 (7.2%)
2c	0 (0%)	0 (0%)
3	0 (0%)	0 (0%)
3a	0 (0%)	0 (0%)
3b	12 (15.6%)	11 (15.9%)
Pathologic M stage
0	77 (100%)	69 (100%)	1
1	0 (0%)	0 (0%)
Presence of T upstaging
Yes	20 (26.0%)	18 (26.1%)	1
No	57 (74.0%)	51 (73.9%)
Presence of N Upstaging
Yes	21 (27.3%)	14 (20.3%)	0.34
No	56 (72.7%)	55 (79.7%)
Presence of T or N Upstaging
Yes	34 (44.2%)	28 (40.6%)	0.738
No	43 (55.8%)	41 (59.4%)